Susquehanna International Group’s Kyverna Therapeutics KYTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$194K Sell
22,500
-16,600
-42% -$138K ﹤0.01% 11739
2025
Q4
$368K Sell
39,100
-7,800
-17% -$57.9K ﹤0.01% 9478
2025
Q3
$281K Buy
46,900
+18,300
+64% +$73.2K ﹤0.01% 10275
2025
Q2
$87.8K Buy
+28,600
New +$70.7K ﹤0.01% 11861
2025
Q1
Sell
-19,800
Closed -$74.1K 13615
2024
Q4
$74.1K Buy
+19,800
New +$94.9K ﹤0.01% 11512

Other funds holding KYTX

Susquehanna International Group's KYTX Position: Q1 2026 in Review

Susquehanna International Group increased its Kyverna Therapeutics (KYTX) stake by 142% in Q1 2026, buying an estimated $2.82M and bringing the position to 577,600 shares worth $4.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

Susquehanna International Group first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Susquehanna International Group held 577,600 shares of Kyverna Therapeutics worth $4.98M as of Q1 2026.
  • Susquehanna International Group bought 338,772 Kyverna Therapeutics shares in Q1 2026, an estimated $2.82M.
  • Kyverna Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4234 holding.
  • Susquehanna International Group first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.